A glimpse of the future: Where will new combinations of diagnostics and therapies take us?

Cancer Journal

Volumn 17, Issue 3, 2011, Pages 190-194

  Alonso Basanta, Michelle ^a   Chapman, Christina ^a   Dorsey, Jay F ^a   Rengan, Ramesh ^a   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CTC; immunotherapy; Molecular imaging; nanotechnology; signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; FOLLICLE STIMULATING HORMONE RECEPTOR; GOLD NANOPARTICLE; HISTONE H2AX; HORMONE RECEPTOR; IPILIMUMAB; NELFINAVIR; PROVENGE; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR IMAGING; NANOTECHNOLOGY; NONHUMAN; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOBIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE;

DIAGNOSTIC IMAGING; HUMANS; IMMUNOTHERAPY; NANOTECHNOLOGY; NEOPLASMS; RADIATION ONCOLOGY; RADIOBIOLOGY; RADIOTHERAPY;

EID: 79958794191     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182216bc0     Document Type: Review

References (59)

1. Park SS, Chunta JL, Robertson JM, et al. MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation. [Published online ahead of print April 12, 2011.] Int J Radiat Oncol Biol Phys.
2. 111In-capromab pendetide SPECT/CT. Radiology. 2011.
3. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol. 2011;21:101-110.
4. Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011;21:88-100.
5. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000;60:6597-6600.
6. Maity A. Modulating the tumor microenvironment to improve radiotherapy. Retina. 2009;29(6 suppl):S32-S33.
7. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al. The Ras radiation resistance pathway. Cancer Res. 2001;61:4278-4282. (Pubitemid 32721000)
8. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18(21 suppl):47S-53S.
9. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356. (Pubitemid 36025259)
10. Bonner JA, Maihle NJ, Folven BR, et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys. 1994;29:243-247. (Pubitemid 24166526)
11. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935-1940. (Pubitemid 29186168)
12. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14:451-463. (Pubitemid 30029793)
13. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-1318.
14. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997;3(12 pt 2):2703-2707. (Pubitemid 28133130)
15. Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269:27595-27602. (Pubitemid 24346592)
16. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328. (Pubitemid 24146785)
17. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311. (Pubitemid 40544648)
18. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
19. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885-892. (Pubitemid 34742122)
20. Gupta AK, Wilke WW, Taylor EN, et al. Signaling pathways in adenoid cystic cancers: implications for treatment. Cancer Biol Ther. 2009;8:1947-1951.
21. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol. 2008;26:2699-2706.
22. PoreN, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res. 2006;66:9252-9259. (Pubitemid 44521147)
23. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007;67:4467-4473. (Pubitemid 46815097)
24. Bernhard EJ, Brunner TB. Progress towards the use of HIV protease inhibitors in cancer therapy. Cancer Biol Ther. 2008;7:636-637.
25. RenganRM R, Pryma D, Lin L, et al. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy (CT-RT) for Stage IIIA/IIIB NSCLC: A Report of Toxicities and Metabolic Response. Chicago, IL: ASTRO; 2009.
26. Hu H, Gatti RA. MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 2010.
27. Kerns SL, Ostrer H, Stock R, et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:1292-1300.
28. Yoon HH, Catalano P, Gibson MK, et al. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 2011.
29. Haffty BG, Goyal S, Kulkarni D, et al. Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT). Int J Radiat Oncol Biol Phys. 2010.
30. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005;2:416-422. (Pubitemid 43115010)
31. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
32. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791. (Pubitemid 39095313)
33. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053-7058. (Pubitemid 350276887)
34. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223-1229.
35. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
36. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14:5013-5021.
37. Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer. Curr Colorectal Cancer Rep. 6:212-220.
38. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-1239.
39. Pinzani P, Salvadori B, Simi L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol. 2006;37:711-718. (Pubitemid 43956539)
40. Kojima T, Hashimoto Y, Watanabe Y, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119:3172-3181.
41. Wang LH, Pfister TD, Parchment RE, et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res. 16:1073-1084.
42. Parsels LA, Qian Y, Tanska DM, et al. Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition. [Published online ahead of print April 11, 2011.] Clin Cancer Res.
43. Yarden Y. The biological framework: translational research from bench to clinic. Oncologist. 2011;16(suppl 1):23-29.
44. Aurer I. Changing therapeutic landscape - the last decade. Transfus Apher Sci. 2011;44:155-159.
45. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722-4729.
46. Mule JJ. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci. 2009;1174:33-40.
47. Shashidharamurthy R, Bozeman EN, Patel J, et al. Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. Med Res Rev. 2011.
48. Eschenburg G, Stermann A, Preissner R, et al. DNAvaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol. 2010;2010:169484.
49. Tabi Z, Spary LK, Coleman S, et al. Resistance of CD45RA-T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. J Immunol. 2010;185:1330-1339.
50. Newcomb EW, Lukyanov Y, Kawashima N, et al. Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouseGlioma model. Radiat Res. 2010;173:426-432.
51. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655-666. (Pubitemid 41400049)
52. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 pt 1):728-734. (Pubitemid 40116901)
53. Tan YN, Su X, Liu ET, Thomsen JS. Gold-nanoparticle-based assay for instantaneous detection of nuclear hormone receptor-response elements interactions. Anal Chem. 2010;82:2759-2765.
54. Karathanasis E, Chan L, Karumbaiah L, et al. Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One. 2009;4:e5843.
55. Bumb A, Regino CA, Egen JG, et al. Trafficking of a dual-modality magnetic resonance and fluorescence imaging superparamagnetic iron oxide-based nanoprobe to lymph nodes. Mol Imaging Biol. 2010.
56. Kessinger CW, Khemtong C, Togao O, et al. In vivo angiogenesis imaging of solid tumors by alpha(v)beta(3)-targeted, dual-modality micellar nanoprobes. Exp Biol Med (Maywood). 2010;235:957-965.
57. Hainfeld JF, Dilmanian FA, Zhong Z, et al. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol. 2010;55:3045-3059.
58. Chanda N, Kan P, Watkinson LD, et al. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine. 2010;6:201-209.
59. Ngwa W, Makrigiorgos GM, Berbeco RI. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement. Phys Med Biol. 2010;55:6533-6548.